

LINFOMI PRIMITIVI CUTANEI DI DERIVAZIONE T-LINFOCITARIA:

la multidisciplinarità ottimizza il risultato


29 OTTOBRE 2021

NAPOLI Hotel Royal Continental

Malattia «Early Stage»: l'Ematologo

Francesco Onida Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico – Università di Milano

MF/SS linee guida di terapia Commissione Linfomi cutanei - FIL



TSEBI: total skinelectron beam irradiation; CT: chemioterapia

Tautinger et al. 2006; Olsen et al. 2007, Olsen et al. 2011 (7, 8, 9)

Coordinate da Nicola Pimpinelli; Autori: Paolo Fava, Silvia Alberti Violetti, Chiara Delfino

LINFOMI PRIMITIVI CUTANEI DI DERIVAZIONE T-LINFOCITARIA: LA MULTIDISCIPLINARITÀ OTTIMIZZA IL RISULTATO

MF/SS THERAPY AT A GLANCE: FIRST LINE

European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017.

F. Trautinger, J. Eder, C. Assaf, M. Bagot, A. Cozzio, R. Dummer, R. Gniadecki, C.D. Klemke, P.L. Ortiz-Romero, E. Papadavid, N. Pimpinelli, P Quaglino, A. Ranki, J. Scarisbrick, R. Stadler, L. Väkevä, M.H. Vermeer, S. Whittaker, R. Willemze, R. Knobler



European Journal of Cancer (2017) 77: pp57-74

	Wait & see	Topical steroids	Photo therapy	Local RT	TSET	Interferon	Bexarotene	Mono-CT	ΜΤΧ	PoliCT	ECP
IA											
IB											
IIA											
IIB											
Ш											
SS											
IVA - IVB											

LINFOMI PRIMITIVI CUTANEI DI DERIVAZIONE T-LINFOCITARIA: LA MULTIDISCIPLINARITÀ OTTIMIZZA IL RISULTATO

MF/SS THERAPY AT A GLANCE: SECOND LINE

European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017.

F. Trautinger, J. Eder, C. Assaf, M. Bagot, A. Cozzio, R. Dummer, R. Gniadecki, C.D. Klemke, P.L. Ortiz-Romero, E. Papadavid, N. Pimpinelli, P Quaglino, A. Ranki, J. Scarisbrick, R. Stadler, L. Väkevä, M.H. Vermeer, S. Whittaker, R. Willemze, R. Knobler

European Journal of Cancer (2017) 77: pp57-74



	Topical steroids	Photo therapy	Local RT	TSET	Interferon	Bexarotene	Mono-CT	МТХ	PoliCT	ECP	HSCT
IA											
IB											
IIA											
IIB											
Ш											
SS											
IVA - IVB											

LINFOMI PRIMITIVI CUTANEI DI DERIVAZIONE T-LINFOCITARIA: LA MULTIDISCIPLINARITÀ OTTIMIZZA IL RISULTATO


CLINICAL PRACTICE GUIDELINES

Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[†]

R Wilemze¹, E. Hodak², P. L. Zinzani³, L. Specht⁴ & M. Ladetto¹, on behalf of the ESMO Guidelines Committee^{*}

"Deserven al Demesting, Leiden University Werkal Deren, Leiden, The Recherkell, "Department of Demessing, Nation Medical Deren, Beilneum Heads, Reach Thea, sees, "Hence of Immessing and Medical Dincolog, University of Biograph, Biograph, Biograph, Biograph, Steiner, Structures, Deren, Steiner, Stein

*CompanyAment to ISMO Guidelines Convoltere, ISMO Head Office, Va Cinevia 6.4805 cupres, Switterland, E-mail chinalguidelinendamen ang *Represent By the ISMO Guideline Convoltere Describer 2006, late: undera January 2016. This publication supresents the previously published version—Ame Oncol 2 M Guidel 61-VFM.




Willemze R et al. Annals of Oncol 2018

LINFOMI PRIMITIVI CUTANEI DI DERIVAZIONE T-LINFOCITARIA: LA MULTIDISCIPLINARITÀ OTTIMIZZA IL RISULTATO

a bear and a strateging of the

The state



NCCN GUIDELINES[®] INSIGHTS


Primary Cutaneous Lymphomas, Version 2.2020

	Preferred Regimens (alphabetical order)	Other Recommended Regimens	Useful Under Certain Circumstances
SYST-CAT A	 Brentuximab vedotin^{i,j,k} Bexarotene^h Extracorporeal photopheresis (ECP)^I Interferons (IFN-alfa-2b^m or IFN-gamma 1b) Methotrexate (≤50 mg q week) Mogamulizumabⁿ Romidepsin^h Vorinostat^h 	• Acitretin ^h • All-trans retinoic acid ^h • Isotretinoin [13-cis-retinoic acid] ^h	
SYST-CAT B	 Brentuximab vedotin^{i,j,k} Gemcitabine Liposomal doxorubicin Pralatrexate (low-dose or standard dose) 		 Relapsed/refractory disease requiring systemic therapy; alphabetical order by category) Alemtuzumab^{k,p} Chlorambucil
Large-cell transformation (LCT)	 Brentuximab vedotin^{i,j,k} Gemcitabine Liposomal doxorubicin Pralatrexate (low-dose or standard dose) Romidepsin See TCEL-B 2 of 5 for regimens listed for PTCL-NOS^o 		 Cyclophosphamide Etoposide Pentostatin Temozolomide for CNS involvement Bortezomib (category 2B) Pembrolizumab (category 2B)^{q,r} See TCEL-B 2 of 5 for regimens listed for PTCL-NOS^o

SUGGESTED TREATMENT REGIMENS^{a,b}

LINFOMI PRIMITIVI CUTANEI DI DERIVAZIONE T-LINFOCITARIA: LA MULTIDISCIPLINARITÀ OTTIMIZZA IL RISULTATO

PROCLIPI is an international prospective database in which all the new cases of mycosis fungoides(MF)/Sézary syndrome are registered after central clinico-pathological review to confirm diagnosis.



the PROCLIPI (PROspective InternationalCutaneous Lymphoma Prognostic Index) study for earlystage MF is a prototype study for international collaborations in rare disease and present our initial findings and central review process.

LINFOMI PRIMITIVI CUTANEI DI DERIVAZIONE T-LINFOCITARIA: LA MULTIDISCIPLINARITÀ OTTIMIZZA IL RISULTATO

MEDICAL	DERMATOLOGY

Treatment of early-stage mycosis fungoides: results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study*

P. Quaglino [0,¹ H.M. Prince,² R. Cowan,³ M. Vermeer,⁴ E. Papadavid,⁵ M. Bagot,⁶ O. Servitjie,⁷ E. Berti,⁸ E. Guenova [0,⁹ R. Stadler,¹⁰ C. Querfeld,¹¹ A.M. Busschots,¹² E. Hodak,¹³ A. Patsatsi,¹⁴ J. Sanches,¹⁵ M. Maule,¹⁶ J. Yoo,¹⁷ M. Kevin,¹⁷ P. Fava,¹ S. Ribero,¹ L. Zocchi,¹ M. Rubatto,¹ M.T. Fierro,¹ U. Wehkamp,¹⁸ M. Marshalko,¹⁹ C. Mitteldorf,²⁰ O. Akilov,²¹ P. Ortiz-Romero,²² T. Estrach,²³ L. Vakeva,²⁴ P.A. Enz,²⁵ M. Wobser,²⁶ M. Bayne,²⁷ C. Jonak,²⁸ M. Rubeta,²⁹ A. Forbes,³⁰ A. Bates,³¹ M. Battistella,⁶ R. Amel-Kashipaz,¹⁷ B. Vydianath,¹⁷ A. Combalia,²³ E. Georgiou,¹⁴ E. Hauben,¹² E.K. Hong,³² M. Jost,¹⁸ R. Knobler,²⁸ I. Amitay-Laish,¹³ D. Miyashiro,¹⁵ J. Cury-Martins,¹⁵ X. Martinez,¹¹ C. Muniesa,⁷ H. Prag-Naveh,¹³ A. Stratigos,⁵ V. Nikolaou,⁵ K. Quint,⁴ C. Ram-Wolff,⁶ K. Rieger,³² R. Stranzenbach,¹⁰ Á. Szepesi,¹⁹ S. Alberti-Violetti,⁸ E. Felicity,¹⁷ L. Cerroni,³³ W. Kempf,³⁴ S. Whittaker,³⁵ R. Willemze,⁴ Y. Kim³² and J.J. Scarisbrick^{17,36}


395 "early stage MF" (stage IA, IB, IIA) included in the database after passing central review process from 01/2015 to 2/2018

Parameter	Number	%
Male	243	62%
Female	152	38
Age median (range)	56 (5-97)	
mSWAT median (range)	10 (0.3-120)	
Europe	349	88%
Outside Europe	46	12%
	40	12/0
Stage IA	198	50%
Stage IB	164	42%
Stage IIA	33	8%
T1a	113	29%
T1b	96	24%
T2a	80	20%
T2b	106	27%
Patches only T1a+T2a	193	49%
Patches + plaques T1b + T2b	202	51%
	71	100/
FMF	71	18%

Quaglino P et al. BJD 2021

LINFOMI PRIMITIVI CUTANEI DI DERIVAZIONE T-LINFOCITARIA: LA MULTIDISCIPLINARITÀ OTTIMIZZA IL RISULTATO

Summary of treatments registered at first visit (first-line therapies)



LINFOMI PRIMITIVI CUTANEI DI DERIVAZIONE T-LINFOCITARIA: LA MULTIDISCIPLINARITÀ OTTIMIZZA IL RISULTATO 29 OTTOBRE 2021 - NAPOLI

La terapia nel paziente ricaduto/refrattario con CTCL


Further treatment lines according to stage

	2nd line (n; %)	3rd line (n; %)	4th line (n; %)	>4 lines (n; %)
IA (n=207)	72; 35%	24; 12%	4; 2%	5; 2%
IB (n=188)	65; 35%	28; 15%	10; 5%	15; 8%
IIA (n=29)	28; 96%	5; 17%	3; 10%	5; 17%
ALL (n=424)	165; 39%	57; 13%	17; 4%	25; 6%
FMF (n=82)	32; 39%	10; 12%	6; 7%	9; 11%

Quaglino P et al. BJD 2021

LINFOMI PRIMITIVI CUTANEI DI DERIVAZIONE T-LINFOCITARIA: LA MULTIDISCIPLINARITÀ OTTIMIZZA IL RISULTATO

Summary of treatments according to the therapy line



1st vs 2nd line Chi square: P<0.001

Quaglino P et al. BJD 2021

LINFOMI PRIMITIVI CUTANEI DI DERIVAZIONE T-LINFOCITARIA: LA MULTIDISCIPLINARITÀ OTTIMIZZA IL RISULTATO

First-line therapies according to the stage

Treatment	All (n; %)	IA (n; %)	IB (n;%)	IIA (n;%)
	N=395	N=198	N=164	N=33
Expectant	29	17	9	3
	(7%)	(9%)	(5%)	(10%)
SKIN-	322	168	131	23
DIRECTED	(82%)	(85%)	(80%)	(70%)
SYSTEMIC	44	14	23	7
	(11%)	(6%)	(14%)	(20%)

The percentage of patients undergoing a first-line systemic approach increased from stage IA to IB to IIA paralleling a decrease in skin-directed therapies (SDT)(particularly in stage IIA. The difference between stage IA-IB and IIA was statistically significant (chi square:15.398; p<0.0001).

Quaglino P et al. BJD 2021

NFOMI PRIMITIVI CUTANEI DI DERIVAZIONE T-LINFOCITARIA: LA MULTIDISCIPLINARITÀ OTTIMIZZA IL RISULTATO

First-line therapies according to T score

	Treatment	T1a (n; %) N=113	T1b (n;%) N=96	T2a (n;%) N=80	T2b (n; %) N=106
	Expectant	8 (7%)	9 (9%)	8 (10%)	4 (3%)
	SKIN- DIRECTED	100 (89%)	76 (79%)	67 (84%)	79 (75%)
	SYSTEMIC	5 (4%)	11 (12%)	5 (6%)	23 (22%)
		T1a T2a		T1b T2b	
		5%		17%	
Chi square: P<0.0)01	SDT SYSTEMIC EXP		SDT SYSTEMIC EXP	Quaglino
		LINFOMI PRIMITIVI CU	JTANEI DI DERIVAZIO		1ULTIDISCIPLINARITÀ OTTIM 29 OT

Multivariate analysis of parameters associated with a more frequent first systemic approach

Variable	Coefficient	Standard error	р	O.R	95% CI low	95% CI high
Geographical	0.7711	0.4636	0.0962	2.1622	0.8715	5.3643
Age	-0.0011	0.0103	0.9146	0.9989	0.9790	1.0192
Gender	-0.0219	0.3543	0.9508	0.9784	0.4886	1.9593
mSWAT	0.1683	0.4283	0.6943	1.1833	0.5111	2.7395
TNM stage	0.4363	0.3003	0.1463	1.5470	0.8587	2.7871
Plaques	1.1221	0.4186	0.0074	3.0712	1.3521	6.9761
FMF	1.0391	0.3641	0.0043	2.8268	1.3846	5.7709

O.R. odds ratio

CI Confidence Interval

FMF: Follicolotropic mycosis fungoides

Quaglino P et al. BJD 2021

LINFOMI PRIMITIVI CUTANEI DI DERIVAZIONE T-LINFOCITARIA: LA MULTIDISCIPLINARITÀ OTTIMIZZA IL RISULTATO

Brentuximab vedotin

	Total No. of	Response		
Diagnosis	Patients (N = 48)	No.	%	Secondary Response (No.)
All patients	48	35	73	
MF	28	13 PR, 2 CR	54	
LyP	9	5 CR, 4 PR	100	
pc-ALCL	2	2 CR	100	
LyP/MF	7	6 LyP CR, 1 LyP PR	100	6 MF PR, 1 MF SD
pc-ALCL/LyP	1	CR	100	1 LyP PD
pc-ALCL/MF	1	CR	100	1 MF PR





Duvic M et al JCO 2015; Kim Y et al. JCO 2015

LINFOMI PRIMITIVI CUTANEI DI DERIVAZIONE T-LINFOCITARIA: LA MULTIDISCIPLINARITÀ OTTIMIZZA IL RISULTATO

29 OTTOBRE 2021 - NAPOLI

50%

5 PR

4 SD, 1PD

58%

1 CR

6 PR

5 SD

1 CR

2 PR

3 SD

Low <10%

(n = 10)

Medium

10 - 50%

(n = 12)

MHigh

≥ 50%

(n = 6)

CD30 expres

ion by IHC

MF/SS, IB-IVB

Phase III ALCANZA Trial

Target accrual (n = 124)

CD30+ CTCL, including MF or pcALCL

≥1 prior systemic therapy No prior treatment with brentuximab vedotin

Study start date: August 2012

Estimated study completion date: June 2015

MF = mycosis fungoides; pcALCL = primary cutaneous anaplastic large-cell lymphoma

- Primary endpoint: ORR lasting ≥4 months
- Secondary endpoints include: Complete response, progression-free survival and changes in burden of symptom domain per Skindex-29 questionnaire

R

Kim YH et al. Proc ICML 2013; Abstract 572.

LINFOMI PRIMITIVI CUTANEI DI DERIVAZIONE T-LINFOCITARIA: LA MULTIDISCIPLINARITÀ OTTIMIZZA IL RISULTATO

Brentuximab vedotin

1.8 mg/kg every 3 weeks for up to 16 cycles

Physician's choice


Methotrexate: 5-50 mg, g1wk

or

Bexarotene: 300 mg/m² qd

Brentuximab vedotin or physician's choice in CD30-positive @⁺ (1) cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial

H Miles Prince*, Youn H Kim*, Steven M Honvitz, Reinhard Dummer, Jolia Scarisbrick, Pietro Quaglino, Pier Luigi Zinzani, Poscil Wolter, Jose A Sannes, Pablo Louris Romero, Gleg F Akliov, Larias Geskin, Judith Trotmon, Keny Toplor, Stephane Dalle, Michael Weichenthol, Jan Walewski, Dowid Fisher, Brigtz Erben, Ruidof Stadler, strayman Gelman, Timothy Miczet, Yinghu Wang, Manic Colimon Palona-Wessels Erin Zagadalov, William: Treptichio, Wenwen Zhang, Hui-Min Lin, Yi Liu, Dirk Huebner, Meredith Litale, Sean Whittakert, Maddeine Durict, on behaff of the Al-KaZka study opurt



	Brentuximab vedotin, n/N (%)	Physician's choice of methotrexate or bexarotene, n/N (%)		Difference in percentages (95% CI)
Mycosis fungoides	24/48 (50.0%)	5/49 (10·2%)	_ —	39·8 (19·9 to 56·2)
pcALCL	12/16 (75.0%)	3/15 (20.0%)	•	55·0 (19·7 to 80·4)
Baseline ECOG PS=0	29/43 (67.4%)	6/46 (13.0%)	_ 	54·4 (37·3 to 71·5)
Baseline ECOG PS≥1	7/21 (33·3%)	2/18 (11·1%) —	•	22·2 (-10·2 to 51·2)
Men	19/33 (57.6%)	5/37 (13.5%)	— •—	44·1 (21·3 to 63·3)
Women	17/31 (54.8%)	3/27 (11.1%)	- _	43·7 (18·5 to 64·7)
Age <65 years	20/36 (55.6%)	2/40 (5.0%)	_ 	50.6 (29.3 to 68.3)
Age ≥65 years	16/28 (57.1%)	6/24 (25.0%)	•	32·1 (6·9 to 57·4)
Europe	23/37 (62.2%)	3/35 (8-6%)	_ 	53·6 (32·7 to 71·3)
Non-Europe	13/27 (48.1%)	5/29 (17.2%)	•	30·9 (4·2 to 53·5)
Bexarotene	36/64 (56-3%)	6/38 (15·8%)	_ 	40.5 (23.7 to 57.3)
Methotrexate	36/64 (56-3%)	2/26 (7.7%)	_ 	48.6 (26.7 to 67.7)
Skin only	21/31 (67.7%)	5/30 (16.7%)	_ 	51·1 (27·3 to 71·0)
Skin and other involvement	15/33 (45.5%)	3/34 (8.8%)	•	36·6 (12·3 to 56·3)
Baseline skin tumour score>0	26/41 (63.4%)	2/38 (5.3%)	— •—	58·2 (38·1 to 74·1)
Baseline skin tumour score=0	10/23 (43.5%)	6/26 (23·1%) -	•	20·4 (-5·5 to 46·3)
Overall	36/64 (56-3%)	8/64 (12.5%)	_	43·8 (29·1 to 58·4)
		-25 Favours physiciar choice of methotrexate or bexarotene	i's Favours brentuximab	7 00


Figure 3: Maximum percent change in skin mSWAT score

mSWAT=modified severity weighted assessment tool. pcALCL=primary cutaneous anaplastic large-cell lymphoma.

Prince HM et al. Lancet 2017

LINFOMI PRIMITIVI CUTANEI DI DERIVAZIONE T-LINFOCITARIA: LA MULTIDISCIPLINARITÀ OTTIMIZZA IL RISULTATO

Phase III ALCANZA Trial



Prince HM et al. Lancet 2017

LINFOMI PRIMITIVI CUTANEI DI DERIVAZIONE T-LINFOCITARIA: LA MULTIDISCIPLINARITÀ OTTIMIZZA IL RISULTATO

Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial

H Miles Prince^{*}, Youn H Kim^{*}, Steven M Horwitz, Reinhard Dummer, Julia Scarisbrick, Pietro Quaglino, Pier Luigi Zinzani, Pascal Wolter, Jose A Sanches, Pablo L Ortiz-Romero, Oleg E Akilov, Larisa Geskin, Judith Trotman, Kerry Taylor, Stephane Dalle, Michael Weichenthal, Jan Walewski, David Fisher, Brigitte Dréno, Rudolf Stadler, Tatyana Feldman, Timothy M Kuzel, Yinghui Wang, Maria Corinna Palanca-Wessels, Erin Zagadailov, William L Trepicchio, Wenwen Zhang, Hui-Min Lin, Yi Liu, Dirk Huebner, Meredith Little, Sean Whittaker†, Madeleine Duvic†, on behalf of the ALCANZA study aroupt

	Brentuximab vedotin				Physician's ch	Physician's choice of methotrexate or bexarotene		
	Total (n=64)	ORR4	ORR	CR	Total (n=64)	ORR4	ORR	CR
ITT population	64 (100%)	36 (56%)*	43 (67%)	10 (16%)	64 (100%)	8 (13%)†	13 (20%)	1 (2%)
Mycosis fungoides	48 (75%)	24 (50%)	31 (65%)	5 (10%)	49 (77%)	5 (10%)	8 (16%)	0
Stage‡§								
IA-IIA	15 (31%)	6 (40%)	8 (53%)	1 (7%)	18 (37%)	4 (22%)	5 (28%)	0
IIB	19 (40%)	12 (63%)	13 (68%)	3 (16%)	19 (39%)	1 (5%)	3 (16%)	0
IIIA-IIIB	4 (8%)	2 (50%)	3 (75%)	0	2 (4%)	0	0	0
IVA	2 (4%)	2 (100%)	2 (100%)	1 (50%)	9 (18%)	0	0	0
IVB	7 (15%)	2 (29%)	4 (57%)	0	0	NA	NA	NA
pcALCL	16 (25%)	12 (75%)	12 (75%)	5 (31%)	15 (23%)	3 (20%)	5 (33%)	1(7%)
Disease involvement‡								
Skin only	9 (56%)	8 (89%)	8 (89%)	4 (44%)	11 (73%)	3 (27%)	5 (45%)	1 (9%)
Extracutaneous disease	7 (44%)	4 (57%)	4 (57%)	1 (14%)	4 (27%)	0	0	0

 \mathcal{Q}^{\uparrow}

Data are n (%). ORR4, ORR, and CR percentages are based on the number of patients in the total column. ORR4= achieved an objective response lasting at least 4 months. ORR=achieved an objective response. CR= achieved a complete response. ITT=intent to treat. NA=not applicable. pcALCL=primary cutaneous anaplastic large-cell lymphoma. *One patient with mycosis fungoides in the brentuximab vedotin group achieved a partial response after C1, C2, and C3, and discontinued because of an adverse event. About 4-3 months later the patient received chemotherapy (gemcitabine) before end-of-treatment visit. Total duration of response, including after receipt of gemcitabine, was 4-8 months. †One patient with pcALCL in the bexarotene group who achieved partial response after C2 and sustained it at C5 chose to withdraw from treatment. The patient received subsequent therapy (methotrexate) about 3-5 months into the response to bexarotene but before end-of-treatment visit. Total duration of response, including after receipt of methotrexate) about 3-5 months into the response to bexarotene but before end-of-treatment visit. Total duration of response, including after receipt of methotrexate, was 4-4 months. ‡Percentage in each subcategory in the total column is based on the number of patients in each disease subtype. §One patient in each group had incomplete staging data and are not included in the table: one patient in the brentuximab vedotin group had partial response and one patient in the physician's choice group had no response.

Table 2: Patient responses by clinical stage at baseline

	Brentuximab vedotin (n=64)	Physician's choice of methotrexate or bexarotene (n=64)	Overall (N=128)
Age (years)	62 (51-70)	59 (48-67)	60 (48-69)
Sex			
Male	33 (52%)	37 (58%)	70 (55%)
Female	31 (48%)	27 (42%)	58 (45%)
Race			
White	56 (88%)	53 (83%)	109 (85%)
Other	5 (8%)	10 (16%)	15 (12%)
Not reported	3 (5%)	1 (2%)	4 (3%)
ECOG PS			
0	43 (67%)	46 (72%)	89 (70%)
1	18 (28%)	16 (25%)	34 (27%)
2	3 (5%)	2 (3%)	5 (4%)
Median CD30 expression*	32-5% (12-5-67-5)	31-3% (12-0-47-5)	31-3% (12-5-60-0)
Time since initial diagnosis (months)	42-2 (12-8-87-4)	37-0 (12-3-102-7)	40-9 (12-7-96-8)
Time since progression on last therapy† (months)	2-4 (1-4-7-9)	1-3 (0-9-3-7)	1-9 (1-1-3-8)
Lines of previous therapy			
Total	4-0 (2-0-7-0)	3.5 (2.0-5.5)	4-0 (2-0-6-0)
Skin-directed	1.0 (1.0-2.0)	1.0 (1.0-2.0)	1-0 (1-0-2-0)
Systemic	2.0 (1.0-4.0)	2.0 (1.0-3.0)	2-0 (1-0-4-0)
Mycosis fungoides	48 (75%)	49 (77%)	97 (76%)
Disease stage‡§			
IA-IIA	15/48 (31%)	18/49 (37%)	33/97 (34%)
IIB	19/48 (40%)	19/49 (39%)	38/97 (39%)
IIIA-IIIB	4/48 (8%)	2/49 (4%)	6/97 (6%)
IVA1	0	1/49 (2%)	1/97 (1%)
IVA2	2/48 (4%)	8/49 (16%)	10/97 (10%)
IVB	7/48 (15%)	0	7/97 (7%)
pcALCL	16 (25%)	15 (23%)	31 (24%)

Prince HM et al. Lancet 2017

LINFOMI PRIMITIVI CUTANEI DI DERIVAZIONE T-LINFOCITARIA: LA MULTIDISCIPLINARITÀ OTTIMIZZA IL RISULTATO

Mogamolizumab

- Mogamulizumab a first-in-class defucosylated humanised IgG1κ moAb, selectively binds to C-C chemokine receptor 4 (CCR4) with enhanced antibody-dependent cellular cytotoxicity activity
- CCR4, which is involved in cell trafficking of lymphocytes to skin, is consistently expressed on the surface of tumour cells in T-cell malignancies, such as cutaneous T-cell lymphoma (including mycosis fungoides and Sezary syndrome), adult T-cell leukaemia-lymphoma, and peripheral T-cell lymphoma
- In phase I/II Trials ORR 38%-42%


NFOMI PRIMITIVI CUTANEI DI DERIVAZIONE T-LINFOCITARIA: LA MULTIDISCIPLINARITÀ OTTIMIZZA IL RISULTATO

Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial

R/R MF or SS (61 centres)

Random Mogamulizumab vs Vorinostat


Stratified by disease subtype and stage




Kim YH et al. Lancet Oncol 2018

LINFOMI PRIMITIVI CUTANEI DI DERIVAZIONE T-LINFOCITARIA: LA MULTIDISCIPLINARITÀ OTTIMIZZA IL RISULTATO

Phase III MAVORIC Trial



Phase III MAVORIC Trial



Kim YH et al. Lancet Oncol 2018

LINFOMI PRIMITIVI CUTANEI DI DERIVAZIONE T-LINFOCITARIA: LA MULTIDISCIPLINARITÀ OTTIMIZZA IL RISULTATO

Phase III MAVORIC Trial

	Mogamulizumab (n=186)	Vorinostat (n=186)
Age, years	64 (54-73)	65 (56-72)
Age group, years		
<65	99 (53%)	89 (48%)
≥65	87 (47%)	97 (52%)
Sex		
Male	109 (59%)	107 (58%)
Female	77 (41%)	79 (42%)
Race		
White	125 (67%)	135 (73%)
Other	37 (20%)	26 (14%)
Not reported*	24 (13%)	25 (13%)
ECOG performance status†		
0	106 (57%)	104 (56%)
1	78 (42%)	82 (44%)
2	2 (1%)	0
Time from initial diagnosis, months‡	41-0 (17-4-78-8)	35-4 (16-2-68-2)
Disease type		
Mycosis fungoides	105 (56%)	99 (53%)
Sézary syndrome	81 (44%)	87 (47%)
Current clinical stage		
IB-IIA	36 (19%)	49 (26%)
IB	32 (17%)	23 (12%)
IIA-IIIB	22 (12%)	16 (9%)
NA ₃	73 (39%)	82 (44%)
NA ₃	19 (10%)	12 (6%)
NBS	4 (2%)	4 (2%)
Number of previous systemic regimens received	3 (2-5)	3 (2-5)
Previous cutaneous T-cell lyr	mphoma therapies	
Bexarotene	107 (58%)	110 (59%)
Interferon	81 (44%)	94 (51%)
Conventional chemotherapy¶	108 (58%)	94 (51%)
Romidepsin	45 (24%)	32 (17%)
Alemtuzumab	19 (10%)	16 (9%)
Pralatrexate	14 (8%)	13 (7%)
Brentuximab vedotin	16 (9%)	4(2%)

	Mogamulizumab	Vorinostat
	(n=186)	(n=186)
Proportion of patients with an overall response by global assessment* †	52/186 (28%)	9/186 (5%)
Overall responses in patient subg	roups	
Mycosis fungoides	22/105 (21%)	7/99 (7%)
Sézary syndrome	30/81 (37%)	2/87 (2%)
Stage IB or IIA	7/36 (19%)	5/49 (10%)
Stage IIB	5/32 (16%)	1/23 (4%)
Stage III	5/22 (23%)	0/16 (0)
Stage IV	35/96 (36%)	3/98 (3%)
Duration of response, months	14.1 (8.4–19.2)	9·1 (5·6-NE)
Mycosis fungoides	13.1 (4.7–18.0)	9·1 (5·6-NE)
Sézary syndrome	17-3 (9-4-19-9)	6.9 (6.9-6.9)
Compartment response*‡		
Skin	78/186 (42%)	29/186 (16%)
Blood	83/122 (68%)	23/123 (19%)
Lymph nodes	21/124 (17%)	5/122 (4%)
Viscera	0/3 (0%)	0/3 (0%)

Data are n/N (%) or median (IQR). The proportion of patients achieving an overall response is based on the Global Composite Response score. NE=not estimable. * Proportion of patients with an overall response or compartmental response is the percentage of patients with confirmed complete response or confirmed partial response. p<0.0001. p=0.0001.

Table 2: Measures of response by investigator assessment

Kim YH et al. Lancet Oncol 2018

LINFOMI PRIMITIVI CUTANEI DI DERIVAZIONE T-LINFOCITARIA: LA MULTIDISCIPLINARITÀ OTTIMIZZA IL RISULTATO

REVIEW ARTICLE				
	RFV	IFW	ART	

BJD British Journal of Dermatology

The importance of assessing blood tumour burden in cutaneous T-cell lymphoma*

M.H. Vermeer 1 J.P. Nicolay (0,2,3,4 J.J. Scarisbrick (15 and P.L. Zinzani (16,7

¹Leiden University Medical Center, Leiden, the Netherlands

² Department of Dermatology, University Medical Centre Mannheim, University of Heidelberg, Mannheim, Germany
 ³Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany
 ⁴Section of Clinical and Experimental Dermatology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
 ⁵University Hospital Birmingham, Birmingham, UK
 ⁶IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
 ⁷Istituto di Ematologia "Seragonoli', Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università degli Studi, Bologna, Italy

Table 1 Classification of peripheral blood involvement in patients with cutaneous T-cell lymphoma (mycosis fungoides or Sézary syndrome)

Original	TNM classification ⁶	ISCL/	EORTC revised classification ¹¹	EORTC-CLWG classification ¹⁴	updated	blood
	Sézary cells circulating in peripheral od (< 5%)	B0 B0a B0b	No significant blood involvement: ≤ 5% of lymphocytes in peripheral blood are atypical T-cell clone negative ^a T-cell clone positive	Recommend object blood class using the assess absolute lyn either CD4 ⁺ CD7 ⁻ CD4 ⁺ CD26 ⁻	flow cytometry nphocyte coun	to ts of
(> : cou nun	ary cells present in peripheral blood 5%); record the total white blood cell int, total lymphocyte count and mber of Sézary cells per 100 iphocytes	B1 B1a B1b B2	Low blood tumour burden: > 5% peripheral blood lymphocytes are atypical but does not meet criteria for B2 class T-cell clone negative T-cell clone positive High blood tumour burden: \geq 1000 Sézary cells per µL or increased CD4 ⁺ or CD3 ⁺ cells with CD4/CD8 ratio of \geq 10 or increased CD4 ⁺ cells with an atypical phenotype (\geq 40% CD4 ⁺ CD7 ⁻ or \geq 30% CD4 ⁺ CD26 ⁻) and a positive T- cell clone	B0 is defined as a μL^{-1} B1 is defined as a μL^{-1} up to 1000 μL^{-1} up to 1000 B2 is defined as a μL^{-1} plus a positi	count of > 25 cells μL^{-1} count of ≥ 10	0 cells 00 cells

Wermeer MH et al . BJD 2021

 It has been reported that patients in either B1 or B2 stage have a 4 to 6-fold greater risk of disease progression than those in B0

- Furthermore, the median survival of patients with B1 or B2 blood involvement is considerably affected compared with B0, independently of disease stage
- A better understanding of which patients with early-stage disease will go on to develop advanced disease is particularly important in this context, as it will help guide treatment choices
- Improving the methodology and extent of blood testing for patients with earlystage MF to establish the proportion of patients with B1- or B2-level blood involvement in stage I–IIA disease is crucial in determining the risk for disease progression in patients with less advanced disease


LINFOMI PRIMITIVI CUTANEI DI DERIVAZIONE T-LINFOCITARIA: LA MULTIDISCIPLINARITÀ OTTIMIZZA IL RISULTATO

The Correlation Between Skin Response and Blood Involvement with Mogamulizumab

Pietro Quaglino¹, Lars Iversen², Reinhard Dummer³, Amy Musiek⁴, Jan-Paul Rosen⁵ ¹University of Turin, Turin, Italy; "Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark; "University Hospital Zurich, Zurich, Switzerland; ¹Division of Dermatology, Washington University in St. Louis, No. USA, ⁵Kyows Kirin International, Marlow, UK

OVERALL POPULATION B0 B1

P139



By courtesy of Pietro Quaglino

LINFOMI PRIMITIVI CUTANEI DI DERIVAZIONE T-LINFOCITARIA: LA MULTIDISCIPLINARITÀ OTTIMIZZA IL RISULTATO

B2

The Correlation Between Skin Response and Blood Involvement with Mogamulizumab


Pietro Quaglino¹, Lars Iversen², Reinhard Dummer³, Amy Musiek⁴, Jan-Paul Rosen⁵ ¹University of Turin, Turin, Italy; ¹Department of Dematology, Aarhus University Hospital, Aarhus, Denmark; ¹University Hospital Zurich, Zurich, Switzerland; ¹Division of Dematology, Washington University In St. Louis, St. Louis, MO, USA; ⁴Kyowa Kirin International, Marlow, UK

OVERALL POPULATION BO

P139



B2



By courtesy of Pietro Quaglino

LINFOMI PRIMITIVI CUTANEI DI DERIVAZIONE T-LINFOCITARIA: LA MULTIDISCIPLINARITÀ OTTIMIZZA IL RISULTATO

Cancer Medicine WILEY

Alitretinoin in the treatment of cutaneous T-cell lymphoma

Till Kaemmerer¹ | Pia-Charlotte Stadler¹ | Leonie Helene Frommherz¹ | Anne Guertler¹ | Lars Einar French^{1,2} | Markus Reinholz¹

	Overall	Mycosis fungoides (MF)	Sézary syndrome		Overall	Mycosis fungoides (MF)	Sézary syndrome (SS)		Overall	Mycosis fungoides (MF)	Sézary syndrome (SS)	Den den de
			(SS)		n = 35	n = 28	n = 7		n = 35	n = 28	$\overline{n=7}$	Duration of alitretinoin
	n = 35	n = 28	<i>n</i> = 7	Single-agent alitretinoin	9 (25.7%)	9 (32.1%)	0	Complete				
Age (years)		56 (26-77)	65 (49-79)	Combinations with alitretinoin INF-a	3 (8.6%)	3 (10.7%)	0	response (CR)	3 (8.6%)	3 (10.7%)	0	29 (16-54)
Stages (TNMB)				ECP	11 (31.4%)	8 (13.8%)	3 (42.9%)	Partial response	10 (28.6%)	9 (32.1%)	1 (14.3%)	18 (3-83)
I				PUVA	4 (11.4%)	3 (10.7%)	1 (12.5%)	(PR)				
IA	5 (14.3%)	5 (17.9%)	0	UVB PUVA + Radiotherapy	3 (8.6%) 2 (5.7%)	2 (7.1%) 2 (7.1%)	1 (12.5%) 0	Stable disease	10 (28.6%)	8 (28.6%)	2 (28.6%)	17 (2-47)
IB	13 (37.1%)	13 (46.4%)	0	PUVA + ECP	3 (8.6%)	1 (3.6%)	2 (28.6%)	(SD)				
п								Progressive	12 (34.3%)	8 (28.6%)	4 (57.1%)	27 (2-80)
IIA	0	0	0		Side e	effets		disease (PD)				
IIB	6 (17.1%)	6 (21.4%)	0									
III				Headache -	2.9%							
IIIA	3 (8.6%)	3 (10.7%)	0	Hair loss -	2.9%							
IIIB	1 (3%)	1 (3.6%)	0	Mental disorder -	8.6%							
IV												
IVA1	7 (20%)	0	7 (100%)	Dermatitis -	2.9%							
				Hypertriglyceridemia -	2	0.0%						
				no side effect-			62.8%					
				1	, ₆	\$ 0	° °					
Kaemmere	er T et al. Can	<i>cer Med 2021</i>			,	percentage						
				PRIMITIVI CUTANE	I DI DERI	VAZIONE T	-LINFOCIT	ARIA: LA MULT	IDISCIPLIN	ARITÀ OTTIM	IZZA IL RISUL	
			an a				4.1					
Filler the the				and the manufacture of the second sec		143-				29011	OBRE 2021 - N	

ACKNOWLEDGEMENT

HSCT UNIT

Giulia Galassi Giorgia Saporiti Maria Goldaniga Federica Grifoni Luca Baldini



DERMATOLOGY UNIT

Prof. Emilio Berti Silvia Alberti Violetti Daniele Fanoni Roberta Piccinno



LINFOMI PRIMITIVI CUTANEI DI DERIVAZIONE T-LINFOCITARIA: LA MULTIDISCIPLINARITÀ OTTIMIZZA IL RISULTATO